Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending September 30, 2023 was $-50.7 Million (a 19.64% increase compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 29.08%
- Annual Consolidated Net Income/Loss for 2022 was $-122 Million (a -26.33% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2021 was $-165 Million (a 4749.47% increase from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-3.41 Million (a 34.84% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending September 30, 2023 was $-172 Million (a 14.2% increase compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss increased by 41.0% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| $-172 Million | $-150 Million | $-137 Million | $-122 Million |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of Prime Medicine, Inc.
Most recent Consolidated Net Income/Lossof PRME including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of Prime Medicine, Inc.
Prime Medicine, Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-50.71 | $-42.39 | $-39.4 | – | – |
| 2022 | $-39.28 | $-29.35 | $-29.35 | $-23.84 | $-121.82 |
| 2021 | – | – | – | $-16.41 | $-165.37 |
| 2020 | – | – | – | – | $-3.41 |
| 2019 | – | – | – | – | $-2.53 |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology